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tors shows great promise for the gene therapeutic treatment
of a broad array of diseases. In fact, the treatment of genetic
diseases with AAV vectors is currently the only in vivo gene
therapy approach that is approved by the US Food and Drug
Administration (FDA). Unfortunately, pre-existing anti-
bodies against AAV severely limit the patient population
that can potentially benefit from AAV gene therapy, espe-
cially if the vector is delivered by intravenous injection.
Here, we demonstrate that we can selectively deplete anti-
AAV antibodies by hemapheresis combined with AAV9 par-
ticles coupled to Sepharose beads. In rats that underwent
hemapheresis and immunoadsorption, luciferase expression
was dramatically increased in the hearts and fully restored
in the livers of these rats. Importantly, our method can be
readily adapted for the use in clinical AAV gene therapy.Received 3 December 2019; accepted 8 January 2020;
https://doi.org/10.1016/j.omtm.2020.01.004.
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Adeno-associated virus (AAV) is a small (25 nm), non-enveloped vi-
rus with a single-strand DNA genome.1 Currently, recombinant
AAV vectors (rAAVs) are arguably the most promising DNA deliv-
ery vehicle for clinical gene therapy. This is due, in part, to the
apparent lack of pathogenicity of the wild-type (WT) virus, the abil-
ity to establish long-term transgene expression, at least in non-
dividing cells,2 and the low immunogenicity when compared to
other viral vectors.
The great potential of rAAVs for clinical gene therapy is exemplified
by the approval by the US Food and Drug Administration (FDA) to
treat patients with Leber’s congenital amaurosis type 2 (LCA2)3 and,
more recently, patients with spinal muscular atrophy (SMA) with an
AAV vector.3 Moreover, preclinical studies to treat severe hemophilia
A and hemophilia B4,5 with rAAVs will likely result in the approval of
these treatments by the FDA in the near future. Unfortunately, there
is a high prevalence of pre-existing anti-AAV antibodies in the gen-
eral population,6–8 which significantly reduces the patient population
that could potentially benefit from AAV gene therapy.
Several strategies have been proposed to overcome this limitation.
But, so far, all of them had limited success. Preliminary studies9192 Molecular Therapy: Methods & Clinical Development Vol. 16 March
This is an open access article under the CC BY-NC-ND license (httphave suggested that one of the most promising strategies might
be plasmapheresis. In traditional plasmapheresis to reduce anti-
bodies in immune diseases, blood cells and the plasma compo-
nents are separated. The plasma is then either replaced by a
plasma replacement solution10 or immunoglobulins are depleted
from the plasma by passing the plasma through protein A
columns.10 The immunoglobulin-depleted plasma and the blood
cells are then combined and reinfused into the patient. Monteilhet
et al.9 have demonstrated in 10 patients that several rounds of
plasmapheresis could lead to a significant reduction in anti-AAV
antibodies. It is noteworthy, however, that for instance for
AAV2, in only one patient (with an initial neutralizing antibody
[NAb] titer of 1/5) all NAbs could be depleted. None of the pa-
tients with an initial neutralizing titer of R10 reached titers that
were consistently below 20.
It is needless to say that multiple plasma exchanges of 50% of total
plasma volume9 is not ideal. Moreover, removal of >90% of all immu-
noglobulins, which would be necessary to drive NAb titers of a patient
with an initial titer ofR1/20 to%2 is not only challenging, but it also
comes with its own set of clinical concerns.
Lazaridis et al.11,12 have designed an improved approach to treat
myasthenia gravis by selectively removing autoantibodies with the
extracellular domain of the acetylcholinesterase receptor immobilized
onto a matrix. A similar approach is used clinically to overcome AB0
incompatibility in renal and liver transplantation by removing anti-
bodies against blood-groups A and B erythrocytes with a column
with immobilized carbohydrate antigens.13,14
Here, we demonstrate that apheresis and an AAV-Sepharose matrix
might be used to overcome the problem of pre-existing anti-AAV an-
tibodies in AAV-based gene therapy.2020 ª 2020 Icahn School of Medicine at Mount Sinai.
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Depletion of Anti-AAV9 Antibodies from an
IVIG Solution by Immunoadsorption with AAV9
Sepharose Beads
(A) Schematic depiction of immunoadsorption of anti-
AAV9 antibodies. To deplete anti-AAV9 antibodies from
a solution with human IVIG (intravenous immunoglob-
ulin), was incubated the solution with Sepharose beads
with covalently coupled AAV9 virions (AAV9-beads). (B)
After incubation with IVIG solution, the beads were
washed with PBS and the anti-AAV antibodies were
eluted from the AAV9-beads by incubation with a low
pH buffer. After elution of the anti-AAV antibodies, the
beads were washed with PBS. The binding/elution
procedure was repeated twice. Anti-AAV9 antibodies in
the eluates were detected by Western blot with
neutralized eluates as a primary antibody. The AAV9
capsid proteins (VP1, VP2, and VP3) were detected with
an HRP-anti-human-IgG secondary antibody and ECL.
The same matrix was reused three times without evi-
dence of loss of binding capacity. (C) As in (B), but with
BSA-beads. (D) Western blot experiment showing the
presence of immunoglobulin heavy chain (HC) and light
chain (LC) in the AAV9-beads eluates. (E) The total
amount of antibodies remained unchanged after the
incubation of IVIG with AAV9-beads, but not with protein
G-beads.
www.moleculartherapy.orgRESULTS
AAV9-Beads Efficiently Reduced Anti-AAV9 Antibodies in
In Vitro Experiments
To fabricate the immunoadsorbent matrix (AAV9-beads), we incu-
bated WT-AAV9 with N-hydroxy-succinmide ester (NHS)-activated
Sepharose (approximately 1.35  1013 viral particles were bound per
mL of NHS Sepharose, data not shown). We then tested whether this
matrix could bind anti-AAV antibodies present in intravenous
immunoglobulin (IVIG). We first incubated an IVIG solution with
AAV9-beads or, as a control, bovine serum albumin (BSA)-beads. Af-
ter washing the beads, we eluted potential anti-AAV9 antibodies byMolecular Therapy: Methods &incubating the beads with pH 3.5 buffer. To
detect anti-AAV9 antibodies, we performed a
Western blot. As can be seen in Figures 1B and
1C, eluate from AAV9-beads, but not BSA-
beads, could detect the three AAV9 capsid pro-
teins (VP1, VP2, and VP3). Unlike with classical
plasmapheresis (using protein A or protein G
columns), the total amount of IgG in the eluate
remained unchanged (Figures 1D and 1E),
whereas protein G beads completely depleted
IgG from the IVIG solution (Figure 1E). More-
over, we were able to re-use the matrix at least
three times without any evidence of loss of bind-
ing capability as demonstrated by an ELISA (Fig-
ure 2). To determine the maximum binding
capacity of the matrix, we incubated increasing
amounts of IVIG with the AAV9-beads(Figure 3). The beads were then washed and the bound antibodies
eluted with low pH buffer. The total amount of bound antibodies
was calculated by ELISA and yielded a maximum capacity
of 120 mg of IVIG/mL of AAV9-beads.
As expected, when we incubated an IVIG solution with AAV9-beads,
the addition of the supernatant to cells did not inhibit AAV9 trans-
duction (Figure 4B). This was not the case when BSA beads were
used (Figure 4B). Furthermore, neutralized supernatant of IVIG incu-
bated with AAV9-beads, but not BSA-beads, strongly inhibited
HEK293T transduction (Figure 4C).Clinical Development Vol. 16 March 2020 193





































































































Figure 2. Analysis of Total Anti-AAV9 Antibody Titers
in the Supernatants and Eluates of the Experiments
Described in Figure 1
(A) Total amounts of anti-AAV9 antibodies in the super-
natants (Figure 1) were determined by ELISA. (B) Total
amounts of anti-AAV9 antibodies in the eluates (Figure 1)
were determined by ELISA. The data are depicted as the
mean ± standard error (n = 3).
Molecular Therapy: Methods & Clinical DevelopmentConfirming our ELISA data (Figure 2), the beads could be used at
least three times to deplete NAbs present in IVIG (Figure 4).
Reduction of Anti-AAV9 Antibodies in Human Samples
To demonstrate that AAV9-beads are also able to deplete anti-AAV
antibodies from individual human sera, we screened human sera sam-
ples and selected 5 sera with NAb titers ranging from 1/4 to 1/128.
After a single round of incubation of the sera with AAV9-beads, we
dramatically decreased both the NAb titers, as well as the total anti-
AAV9 antibodies (Figure 5; Table S1). The modest reduction of
NAbs and total-anti-AAV antibodies in human serum 5 (NAb titer
of 1/128) was likely due to the fact that this serum exceeded the bind-
ing capacity of the beads. Interestingly, in the experiments with hu-
man serum 1 (NAb titer of 1/4), transduction at a serum dilution
of 1/2 was not fully restored. Similarly, the depletion of immunoglob-
ulins of human serum 1 was incomplete. Because both neutralizing
and non-neutralizing immunoglobulins bind to AAV9 beads, the
easiest explanation for the lack of complete restoration of transduc-
tion by incubation with AAV9 beads is that the binding of non-
neutralizing immunoglobulins prevented the complete depletion of
neutralizing factors. In fact, our data—compare our NAb results
with our ELISA results (e.g., human serum 4; NAb titer 1/32)—and
data by others15 demonstrate that the correlation of ELISA and
NAb results depends on the specific human serum analyzed. The
presence of neutralizing factors against AAV9 in the general popula-
tion is low. In fact, among the 10 sera tested for (Figure 5), only 5 were
positive for neutralizing factors in our NAb assay. Nonetheless, even
in the absence of depletion experiments of multiple low NAb titer194 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020samples, taken together, our in vitro experiments
conclusively demonstrate that AAV9-beads can
deplete NAbs and potential other neutralizing
factors from human sera—even with a single
round of incubation with AAV9 beads.
Similarly to AAV9, incubation of IVIG with
AAV2 coupled to beads was able to deplete
neutralizing antibodies/factors from IVIG solu-
tions (Figure S1). Thus, our approach is likely
applicable to many AAV serotypes and variants.
It has recently been reported that AAV5 has an
unusual immune profile.16–18 For instance, a
recent publication suggests that non-human pri-
mates with NAb titers of an average of >5,000show only a 2.9-fold reduction in transduction compared to animals
that are negative for NAbs.18 Unfortunately, a detailed description of
the NAb assay is not provided by Ferreira and colleagues.18 However,
a thorough investigation of the literature cited in Salas et al.18 (and of
relevant articles that have been cited in articles referenced in their
publication16,17) suggests that in their NAb assay, the number of
vg-containing particles per mL serum is 3.8  105.
In our NAb assay, on the other hand, we used 1  107 vg-containing
particles/mL serum. Put differently, had we used the same number of
vg-containing particles/mL serum that was apparently used by Salas
et al.,16–18 our NAb titers of 1/4 and 1/128 would translate to NAb
titers of 106 and 3,368, respectively. Clearly, the AAV gene therapy
community—at the very least—needs to modify the way of reporting
of neutralizing AAV transduction capacities of sera to be able to
compare NAb titers among different articles.
This is critical since, for the reasons just described, it is currently diffi-
cult to judge whether systemically delivered AAV5 is truly less sensi-
tive to anti-AAV5 antibodies when compared to the sensitivity of
other serotypes to antibodies against the serotype administered
(e.g., Salas et al.18 and Falese et al.)15
In Vivo Immunoadsorption of Anti-AAV Antibodies
Because of the small blood volume of rats, plasmapheresis is chal-
lenging. However, Lazaridis et al.11 have demonstrated that whole-
blood apheresis can be performed in rats after an implantation of a
femoral vein catheter. To test whether we could use hemapheresis
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Figure 3. Binding Capacity for Anti-AAV9 Antibodies
50 mL AAV9-beads or BSA-beads were incubated with increasing concentrations of
IVIG. The coupled antibodies were eluted and the amount of anti-AAV9 antibody
bound was determined by ELISA. The data are depicted as the mean ± standard
error (n = 3).
www.moleculartherapy.organd an AAVmatrix to deplete anti-AAV antibodies from the blood of
rats, we used a similar approach. To gain blood access, we implanted a
catheter into the jugular vein of the rats.
Initially, we attempted to use active immunization to obtain a
group of animals with an appropriate range of NAb titers. Unfor-
tunately, the variability in neutralizing titers (using different
amounts of virus as antigen) was too unpredictable to be practical
(and humane) for our experiments. Hence, we decided to use a
passive immunization method for the experiments described
here. A single intradermal injection of serum from a rat with a
very high anti-AAV titer was used to passively immunize the
rats. This allowed us to predict with reasonable accuracy the
neutralizing titer after 24 h, which (without immunoadsorption)
stayed constant for at least 3 days (Figure S2).
After a single round of hemapheresis, we observed a rapid rebound of
antibodies from the interstitial/lymphatic compartment. In fact, 3 h
after hemapheresis the concentration of neutralizing antibodies/fac-
tors exceeded 60% pre-hemapheresis levels, and at 24 h the levels
were equal to the antibody/neutralizing fact levels before the first he-
mapheresis session (Figure S3A). As has been shown in by Kotchey
et al.19 in mice, the blood clearance of AAV9 was slow. In our exper-
iments in rats, even 24 h after virus injection the concentration of
AAV9 was essentially unchanged when compared to levels 2 h after
virus injection (Figure S3B). In order to mitigate the effect of antibody
rebound on transduction, we performed 3 consecutive immunoad-
sorption sessions, 1 h apart. In each session, approximately 1 blood
volume was drawn, incubated with beads, and then re-infused into
the rat (for details see Materials and Methods). Blood samples were
taken before and after each session. Figure 6 shows the results of
NAb assays and ELISA from sera samples from 2 representativeMolecularrats with initial NAb titers of 1/8 and 1/16, respectively. In contrast
to their base line titers, none of the rats had any NAbs in their blood
(Figure 6B) and their total anti-AAV antibodies were dramatically
reduced (Figure 6C).
Immediately after the last session, the rats were tail vein injected
with AAV9-luciferase (8  1012 vg/kg). Control rats with corre-
sponding NAb titers were injected with an equal amount of
AAV9-luciferase.
21 days after viral injection (Figure 7A), we performed in vivo imag-
ing to evaluate viral transduction. In sharp contrast to control rats,
rats whose NAbs were depleted with immunoadsorption showed sig-
nificant expression of luciferase in the liver/heart and skeletal muscle
area. The data for pairs of rats with NAb titers of 1/8 and 1/16 are
shown in Figures 7B and 7C, respectively. The data for other rats
are shown in Figure S5.
At the time of sacrifice (day 28, Figure 7A), the heart, liver, and
skeletal muscle (quadriceps) of the rats were collected and lucif-
erase expression was accurately quantified in vitro. In all rats
that were passively immunized, but were not subjected to immu-
noadsorption, luciferase expression was reduced >50,000-fold
when compared to naive rats (Figures 7B and 7C). In sharp
contrast, luciferase expression in the heart and liver in rats that
had undergone immunoadsorption was dramatically increased
(Figures 7B and 7C). In fact, expression in the livers was equal
to expression levels in the livers of naive rats. On the other
hand, while there was a clear trend toward increased transduction
of muscle of rats that had undergone immunoadsorption, the in-
crease was not statistically significant (Figure 7).
DISCUSSION
The administration of AAV as a gene therapy vector is currently a
resource used in the clinic for the treatment of LCA23 and patients
with SMA.3 Additionally, recent promising data from hemophilia
clinical trials corroborate the enormous potential of this vector
showing that AAV can efficiently transduce liver when it is injected
systemically.
The humoral immune response against AAV due to exposure to the
WT virus is a significant obstacle for AAV-based gene therapy, espe-
cially if the vector is injected systemically. The presence of even very
low titer of NAbs can severely reduce or even block the transgene de-
livery into the target organ. For this reason, the current approach to
address this problem is to exclude seropositive patients from these
therapies. Moreover, for the successful treatment of certain diseases,
re-administration of the virus will be necessary. In these cases,
although the patient was seronegative at the time of the first AAV vec-
tor administration, the humoral immune response induced by the
initial vector administration will prevent the successful transduction
upon repeat vector delivery. A number of different strategies have
been proposed to circumvent this limitation of AAV-based gene ther-
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Figure 4. IVIG but Not Supernatants of IVIG Solutions
Incubated with AAV9-Beads Inhibit Transduction of
HEK293T Cells with AAV9-Luc
(A) Anti-AAV9 antibodies were depleted from human IVIG
solutions by incubation with AAV9-beads (BSA-beads
served as a control). The same beads were used for three
rounds of depletion (see Figure 1 and text). (B) 2-fold di-
lutions of the supernatants of the IVIG solutions with AAV9-
beads or BSA-beads were used to detect transduction of
HEK293T cells by an AAV9 vector-encoding luciferase
(AAV9-Luc). For details, see Materials and Methods sec-
tion. (C) After the incubation with the AAV9-beads or BSA-
beads, bound anti-AAV9 antibodies were eluted with low
pH buffer. Neutralized supernatants were then used to
detect the presence of neutralizing antibodies against
AAV9 as described in (B). The transduction efficiency is
expressed as percent of no-serum control samples. The
data are depicted as the mean ± standard error (n = 3).
Molecular Therapy: Methods & Clinical Developmentcapsid-decoys, capsid engineering, the administration of
immunosuppressants, and direct injection of the AAV in the target
tissue.20–23
In this report, we describe the preparation of an immunoadsorbent
matrix for anti-AAV9 antibodies, which can be used for the elimina-
tion of anti-AAV9 antibodies in IVIG solution or in human serum.
We also show that the reduction of antibodies was specific for anti-
bodies against AAV9, while no significant reduction in total anti-
bodies was observed. Of note, using an immunoadsorbent matrix
for AAV2 antibodies, we were also able to deplete anti-AAV2 anti-
bodies from IVIG solutions (Figure S1), indicating that our approach
is likely broadly applicable to multiple AAV serotypes and variants.196 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020Moreover, we show that the combination of im-
munoadsorption and hemapheresis efficiently
reduces the presence of neutralizing antibodies
against AAV9 in rats that were passively immu-
nized with anti-AAV9 serum. Due to the signif-
icant antibody reservoir in the interstitial fluid
and the ensuing “rebound effect” (Figure S3),
we performed 3 rounds of immunoadsorption,
each 1 h apart. Surprisingly, we didn’t observe
any differences in neutralizing antibodies in
sera collected between the sessions. Interestingly,
in contrast to our results obtained with a NAb
assay, we saw a clear decline in total anti-AAV
antibody levels, as measured by ELISA experi-
ments, after each immunoadsorption session.
The transduction of all organs tested in rats with
initial neutralizing titers of 1/8 or 1/16 was
completely inhibited by the NAbs (Figure 7).
However, when AAV9-Luc was injected after
the last session of the hemapheresis and immu-
noadsorption, the transduction levels in the heartdramatically increased and luciferase expression was completely
restored in the liver (Figure 7). Although there was a clear trend to-
ward increased luciferase expression in muscle, the increase was not
statistically significant (Figure 7).
As we have shown in Figure S4A, NAb titers recovered by more than
50% 3 h after transduction and were fully restored at 24 h. In contrast
to most organs, blood vessels in the liver have extraordinarily large
fenestrations: 280 nm.24 This means that the virus (with a diameter
of25 nm) that escapes into the liver likely does so during “first pas-
sage.” Because of this, this virus is not subject to an anti-AAV anti-
body rebound effect (Figure S3), which likely explains the complete
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Molecular Therapy: Methods & Clinical DevelopmentIn contrast to the liver, the vasculature in skeletal muscle and in the
heart has fenestrations of only 5 nm.24 These small fenestra almost
certainly limit the efficacy and kinetics of escape of AAV from the
vasculature. In non-immunized animals, the titers of AAV9 in the
blood do not decline significantly for at least up to 3 days (Figure S3B).
This should allow the continued escape from vessels with small fen-
estrations and the potential transduction of skeletal myocytes or
cardiomyocytes.
In immunized animals that underwent hemapheresis, NAb titers
rapidly rebound (60% at 3 h). As a result, AAV9 particles in the
blood stream will be rapidly neutralized and can no longer transduce
skeletal myocytes or cardiomyocytes, even after escape from the
vasculature. This likely explains the more modest enhancement of
transduction of the heart and the limited, though not statistically sig-
nificant, increase in the transduction of muscle (Figure 7). The easiest
explanation for the more pronounced enhancement of transduction
in the heart, when compared to skeletal muscle, in animals that un-
derwent hemapheresis, is the 10-fold higher capillary density in
the heart when compared to skeletal muscle.25
Because the virus stays in the blood circulation for a long time (Fig-
ure S3B), it is likely that transduction in the heart, and especially in
muscle, could be enhanced further by repeated immunoadsorption
over a number of weeks. Unfortunately, all our attempts to do so
failed because the rats managed to remove their catheters (despite be-
ing housed in individual cages).
In conclusion, here we demonstrate, for the first time, that antibodies
against AAV can be selectively depleted from the blood of animals by
using hemapheresis and AAV-beads. To our knowledge, we report
the first in vivo depletion of anti-AAV specific antibodies ever pub-
lished. Significantly, our immunoadsorption technique allows the
successful transduction of the heart and liver (and to a lesser extent
muscle) of animals that without immunoadsorption wouldn’t show
any transduction as a result of NAbs.
Most importantly, we expect that our approach will be readily trans-
latable into the clinic and that it will allow the treatment of a much
larger number of potential patients that could benefit from gene ther-
apy with AAV vectors.
MATERIALS AND METHODS
Animal Procedures
All procedures involving the handling of animals were approved by
the Institutional Animal Care and Use Committee (IACUC) of the
Icahn School at Mount Sinai and adhered with the Guide for the
Care and Use of Laboratory Animals published by the National Insti-
tutes of Health. All animals were provided with nesting material, hadFigure 5. Depletion of Anti-AAV Antibodies in Human Serum Samples by Immu
In vitro depletion of anti-AAV9 antibodies from 5 human sera with neutralizing titers of 1/4
described in Figure 1. Neutralizing antibody titers were determined as in Figure 2, and tot
the mean ± standard error (n = 3). Western blot was used to confirm that the antibodies
198 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchad libitum access to food and water, and were housed in a facility with
a 12 h/12 h light/dark cycle.
In Vitro Immunoadsorption
WT-AAV9 or WT-AAV2 was coupled to NHS-Activated Sepharose 4
Fast Flow (cat. no: 17090601, GE Healthcare), according to the manu-
facturer’s instructions. NHS-activated Sepharose (beads) was washed
with 15 gel volumes of cold 1 mM hydrochloric acid to remove the iso-
propanol in the storage solution. The pH of theWT-AAV solution was
adjusted to pH 8.3, added to the beads in PBS, and incubated overnight
at 4C with mechanical rotation. Approximately 1  1014 WT-AAV9
particles were incubated with 25 mL of NHS-Sepharose. For WT-
AAV2, approximately 1  1013 particles were incubated with 2 mL of
NHS-Sepharose. Sepharose beads coupled with 10 mg of albumin
(BSA) were used as a control. After the coupling reaction, the non-re-
acted groups of the beads were blocked with 0.1 M Tris hydrochloride
(pH 8.5) for 1 h with agitation at room temperature. The beads were
then washed consecutively with buffer A (0.1 M acetate buffer, 0.5 M
NaCl, pH 4) and buffer B (0.1 M Tris hydrochloride buffer, pH 8).
The beads were washed 5 times. Each time, 3 volumes of washing solu-
tions were used. The beads were kept at 4C in PBS solution. The
coupling efficiency was determined with SDS-PAGE followed by Coo-
massie staining to visualize the AAV capsid proteins or BSA before and
after the incubation with NHS-activated Sepharose.
For the in vitro experiments, 200 mL of the AAV-beads or BSA-beads
were mixed with 400 mL of dilutions of human serum or IVIG and
incubated for 20 min at room temperature. For the elution of immu-
noglobulins bound to the beads, the beads were first washed with 5
times with 10 bead volumes of PBS. Then 0.5 bead volume of
0.1 mM citric pH 3.5 was added followed by incubation for 5 min
at room temperature. After pelleting the beads, the supernatant was
immediately neutralized by adding 0.1 volume of 1MTris hydrochlo-
ric acid, pH 8.
In Vivo Hemapheresis and Immunoadsorption
Catheter Implantation
The rat was placed in a chamber exposed to 4% isoflurane and oxygen
(1 L/min) until the rat was anesthetized. The rat was intubated with a
16G catheter and connected to a ventilator set to 70 breaths/min with
2%–2.5% isoflurane. The surgical areas (back and neck) were shaved
and then cleaned with 10% povidone-iodine solution followed by 70%
ethanol. The animal was placed on top of sterile drapes. The first inci-
sion wasmade on the rat’s back, in the center just below the shoulders.
Using a long hemostat, a channel was made for the catheter to the
right side of the neck. Next, the animal was flipped over and a small
incision was made on the right lateral side of the neck, above the sub-
clavian junction. Once the jugular vein was exposed, 3-0 prolene su-
ture was used to prevent bleeding. The catheter was flushed with 1%noadsorption
, 1/8, 1/16, 1/32, and 1/128, respectively. Incubation and elution was performed as
al anti-AAV9 antibodies amounts were quantified by ELISA. The data are depicted as




















































































































































Hem. 2 Hem. 3
Baseline
Figure 6. Hemapheresis and Immunoadsorption with
AAV9 Beads Depletes Anti-AAV9 Antibodies from the
Blood of Passively Immunized Rats
(A) Experimental scheme of the depletion protocol. At day
0, catheters were implanted into the jugular vein of rats that
were passively immunized with anti-AAV9 rat serum. On
day 1, rats underwent three rounds of hemapheresis and
immunoadsorption with AAV9 beads. Blood was drawn
immediately before the first hemapheresis session (base-
line) and immediately after each round of hemapheresis.
Immediately after the last hemapheresis session, 8  1012
vg/kg of AAV9-Luc was injected. (B) Sera from the blood
samples described in (A) were used for neutralization as-
says (see Figure 2). (C) Total anti AAV9 antibodies were
determined by ELISA (for details, see Materials and
Methods section). The data are expressed as the per-
centage of total-anti AAV9 antibodies at baseline.
www.moleculartherapy.orgheparin solution. The catheter was then inserted into the neck inci-
sion and threaded through the channel until the end of the catheter
emerged from the back incision. A 1 mL syringe with 1% heparin
was placed on that end. The other end of the catheter was marked
with the distance from the incision to the inferior vena cava. Using
small vascular scissors, the vein was cut slightly above the subclavian
junction (to prevent disrupting the venous circulation to the upperMolecular Therapy: Methods &body). The previously placed control suture
was kept tight to avoid bleeding. Using small,
fine vascular forceps, the marked end of the cath-
eter was inserted into the jugular vein up to the
mark on the catheter. Another suture was tied
to secure the catheter into the jugular vein. We
made sure that the catheter worked by aspirating
blood from the syringe. When blood easily made
its way through the catheter and into the syringe,
the catheter was flushed with 1% heparin-saline
and secured with Vetbond. The incision on the
neck was closed. The animal was then turned
over. Once we confirmed the blood was flowing
through the catheter easily, the catheter was
flushed and secured with Vetbond and the inci-
sion on the back was closed. We cut the extra
length of the catheter so that only 2 inches
were exposed. To prevent clotting, we filled the
catheter with 0.1–0.2 mL of heparin-glycerin
mixture (500 IU heparin/mL in 50% glycerin;
HGS-10, SAI Infusion Technologies) solution
and sealed by inserting a stainless steel tip. The
catheter was secured to the rat’s back in a loop
using discrete sutures and Vetbond so that that
the rat could not remove it. After the surgery,
we turned off the isoflurane but continued to
administer oxygen to the animal via the endotra-
cheal tube. When the animal started making
spontaneous breathing motions and neck move-ments and responded to physical stimuli, we extubated the rat and
disconnected the ventilator. The animal was then placed (and kept)
in a separate cage to recover.
Hemapheresis and Immunoadsorption
For in vivo experiments, immunoadsorption columns were con-
structed as described previously.11 Briefly, a nylon net filter 40 mmClinical Development Vol. 16 March 2020 199
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Figure 7. Depletion of Anti-AAV9 Antibodies by Hemapheresis and Immunoadsorption from the Blood of Passively Immunized Rats Allows the Successful
In Vivo Transduction with AAV9-Luc
(A) Timeline of experiment. (B) Expression of luciferase determined by in vivo imaging (day 21; left) and luciferase expression measured in vitro (day 28; right) in tissue of the
heart, liver, and skeletal muscle harvested at the day of sacrifice. The average of background luminescence in tissues of uninjected rats (n = 4) was subtracted from the values
obtained in animals that were injected with AAV-Luc. The neutralizing titer of immunized animals or of immunized animals before hemapheresis and immunoadsorption was
1/8. Naive animals (n = 10), immunized (n = 6), immunized plus hemapheresis and immunoadsorption (n = 5). NC, not calculable because the values of immunized rats were
below zero RLU/mg (relative luciferase units/mg protein) (C) As in (B) but the neutralizing titer of immunized animals or of immunized animals before hemapheresis and
immunoadsorption was 1/16. Naive animals (n = 10), immunized (n = 5), and immunized plus hemapheresis and immunoadsorption (n = 5). Boxes correspond to upper and
lower quartiles, the horizontal line represents the median, and the whiskers mark the minimum and maximum values. The fold differences in expression levels and p values
among the groups are indicated. Statistical analysis was done by Mann-Whitney test. See also Figure S4 and for raw data see Table S2.
Molecular Therapy: Methods & Clinical Developmentpore diameter (Millipore) was glued to the bottom of a 5 mL syringe
close to the needle adaptor. The pore of the filter allowed the passage
of blood cells but not the beads. For the hemapheresis, rats were anes-
thetized with 4% of isoflurane and oxygen and attached to the venti-
lator via a nose cone. A syringe containing 2 mL of AAV9-beads (see
above) was attached to the catheter. 2 mL of blood was drawn into the
syringe filled with AAV9-beads and immediately returned to the cir-
culation. This procedure was repeated 10 times in three different ses-
sions, each 1 h apart. Before and after each session, blood samples
were collected and the sera were used for neutralizing antibody assay
and ELISA experiments. Immediately after the last hemapheresis/im-
munoadsorption session, 8  1012 vg/kg of AAV9-Luc were injected
into the tail vein. After the incubation with the serum solution, the
beads were washed with 2 volumes of PBS 5 times and incubated
with 0.5 volume of citric acid 0.1 mM solution pH 3.5 for 5 min. After
the incubation, the beads were pelleted and the supernatant was200 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchimmediately neutralized by adding 0.1 volume of Tris hydrochloride
1 M pH 8. The beads were washed again with 2 volumes of PBS 5
times and reused in another round of hemapheresis. The beads could
be regenerated at least 3 times.
Preparation of WT-AAV and Recombinant AAV-Luc
Recombinant AAV9-Luc or AAV2-Luc was produced essentially as
previously described.20 The day before transfection, triple flasks (total
surface area 500 cm2) were each seeded with one confluent 15 cm dish
of HEK293T/17 (CRL-11268, ATCC) cells and incubated overnight at
37C and 5% CO2. Once 90% confluence was reached, transfection
was performed by adding the following to 20mL of room temperature
DMEM: 50 mg of cis-plasmid (firefly luciferase from pCMV-GL3),
150 mg of pDG9 or pDG2 (briefly vortex), and 250 mL of PEI-max
(Polysciences) solution (pH 4.5). ForWT-AAV9 andWT-AAV2 pro-
duction, 66 mg of pAV9 or pAV2 plasmid and 133 mg of pHELPER2020
www.moleculartherapy.orgwere used. The solution was vortexed for 10 s and incubated at room
temperature for 15 min. The transfection mix was then added to
90mL of pre-warmed DMEM containing 2% FBS andmixed by swirl-
ing. The medium from the triple flasks was removed and replaced
with the transfection mixture. After 3 days of growth, the cells were
harvested by vigorous tapping of the flask, transferred to a sterile
container, and pelleted by centrifugation. The supernatant was kept
for downstream processing. The cell pellet was resuspended in
5 mL of lysis buffer (150 mM of NaCl, 50 mM of Tris hydrochloride,
pH 8.5, and 2mMofMgCl2), and freeze-thawed three times at80C
and 37C with brief vortexing after each thaw cycle. Non-encapsi-
dated DNA and contaminating RNA was then digested by adding
2 mL (10 IU/mL) of Pierce Universal Nuclease (cat. no.: 88700,
Thermo Fisher Scientific) followed by incubation for 30 min at
room temperature. The crude cell lysate was centrifuged to pellet
debris, and the supernatant was reserved for iodixanol (cat. no.:
D1556, Sigma-Aldrich) gradient ultracentrifugation. Virus from the
cell culture supernatant was precipitated by the addition of 31.3 g
of ammonium sulfate per 100 mL of supernatant followed by incuba-
tion on ice for at least 30 min. The precipitate was pelleted via centri-
fugation, resuspended in 5mL of lysis buffer, and then combined with
the cell pellet supernatant for iodixanol gradient ultracentrifugation.
Samples for ultracentrifugation were prepared in 32.4 mL of polypro-
pylene Optiseal tubes (Beckman Coulter). Viral lysates were loaded
on top of discontinuous iodixanol gradients composed of 4 mL of
60% iodixanol, 4 mL of 40%, 4.9 mL of 25%, and 7.3 mL of 17%
(with 1 M sodium chloride). The gradients were centrifuged at
350,333  g (avg) for 60 min at 18C in a Beckman type 70 Ti fixed
angle rotor. Fractions (1.25mL) were collected from the bottom of the
tube and kept for virus titration. Peak fractions were dialyzed in
lactated Ringer’s solution (Baxter International), filtered through a
0.22 mm pore filter (Merck Millipore), and stored at 80C.
Neutralization Assay
293T/17 cells (ATCC CRL-11268) were maintained in DMEM sup-
plemented with 10% FBS and 1% penicillin/streptomycin at 37C
and 5% CO2. 1  104 cells/well in medium with penicillin/strepto-
mycin were seeded into 96 well-plates (cat. no.: 08-772-2C; Thermo
Fisher Scientific) and incubated overnight. The following morning,
2-fold serial dilutions of the sera, IVIG, or eluate solutions were pre-
pared in DMEM in a separate 96-well plate. The concentrations
ranged from 40 mL undiluted solution to 1/64 diluted solution. Wells
with the same volume of DMEM served as no-serum controls. 2 
108/well viral genomes of AAV-Luc in 40 mL of DMEM were added
to the sera samples or the DMEM control wells (in triplicate), incu-
bated at 37C for 30 min, and then added to the 293T cells. 24 h later,
the transduction efficiency was analyzed by quantifying luciferase ac-
tivity. The percentage of inhibition was calculated relative to positive,
no-anti-AAV (DMEM) control samples. The highest dilution
with <50% transduction efficiency was defined as the NAb titer.
Luciferase Assay
The 293T/17 cells for the luciferase assay analysis were lysed by
adding an equal amount of 2 lysis buffer (25 mM Tris hydrochlo-Molecularride pH 8, 2 mM DTT, 2 mM EDTA, 10% glycerol, and 1% Triton
X-100) followed by an incubation at room temperature on a shaker
for 10 min. 20 mL of the cell lysates were added to a black 96-well
FluoroNunc plate (cat. no. 12-565-275; Thermo Fisher Scientific).
For rat tissues, approximately 25 mg of pulverized tissue from
each organ was mixed with 500 mL of lysis buffer, vortexed for 15
s, and then agitated at room temperature for 15 min. The samples
were subjected to three cycles of freeze thawing at 80C to 37C
with brief vortexing after each thaw cycle and incubated overnight
at 4C with agitation. The next day, samples were centrifuged at
12,000  g for 3 min to pellet debris. Protein concentrations were
determined by a BCA (bicinchoninic acid) protein assay (cat. no.:
23227; Pierce, Thermo Fisher Scientific) according to the manufac-
turer’s instructions. The luciferase reaction was initiated by the
addition of 100 mL of the reaction buffer (25 mM Tricine hydro-
chloride pH 7.8, 5 mM magnesium sulfate, 0.5 mM EDTA, pH
8.0, 3.3 mM DTT, 0.5 mM ATP pH 7–8 [A26209; Sigma-Aldrich],
1 mg/mL BSA, 0.05 mg/mL D-luciferin [cat. no.: LUCK-100, Gold
Biotechnology], 0.05 mM co-enzyme A [cat. no.: 13787, United
States Biological], and was read in a luminescence counter (Mi-
crobeta Trilux 1450 LSC Luminescence Counter; Perkin Elmer).
In Vivo Imaging
In vivo luciferase expression was analyzed 21 days after the injection
with AAV9-Luc. Rats were anesthetized with 4% of isofluorane and
placed in the imaging chamber of a Xenogen IVIS system (Xenogen,
Alameda, CA, USA); anesthesia was maintained throughout the pro-
cedure. Rats were injected via the tail vein with 150 mg Luciferin/kg
body weight (cat. no.: LUCK-100; Gold Biotechnology). A picture of
the animals was taken, followed by bioluminescence image acquisi-
tion. Light intensity was quantified as photons/seconds/cm2/sr. The
color scale was normalized for all sets of images acquired.
ELISA
ELISA plates (cat. no.: 44-2404-21, Nunc MaxiSorp flat-bottom, In-
vitrogen) were coated with 1  1010 WT-AAV9 viral particles per
well, overnight at 4C. The WT-AAV9-coated plates were washed
with 300 mL of PBS buffer per well and blocked with 300 mL of
5% non-fat milk in PBS for 1 h. In a separate 96-well plate,
2-fold serial dilutions of the sera, IVIG, or eluate solutions in 10%
milk TBS-Tween (Tris Buffer Saline Tween) (Tris hydrochloride,
20 mM; NaCl, 150 mM, and Tween 20, 0.1%) were prepared and
then incubated in the ELISA plate for 1 h at room temperature. Af-
ter the incubation, the plate was washed 3 times with 300 mL of
TBST (0.05%, v/v) per well and incubated for 1 h with goat
anti-rat IgG-horseradish peroxidase (HRP) H&L (cat. no.:
ab97057, Abcam; 1:10,000 in 5% fat-free milk in TBS-Tween) or
rabbit anti-human IgG-HRP H&L (cat. no.: ab6759, Abcam;
1:10,000 in 5% fat-free milk in TBT-Tween). After washing each
well 3 times with 300 mL of TBST the plate was incubated with
HRP substrate SIGMAFAST OPD (P9187, Sigma-Aldrich) for
10 min followed by the addition of HCl 3 M to stop the reaction.
The plate was read at 492 nm on a multiwell plate reader (Molecular
Devices, SpectraMax).Therapy: Methods & Clinical Development Vol. 16 March 2020 201
Molecular Therapy: Methods & Clinical DevelopmentWestern Blot
1  109 AAV9 or AAV2 viral particles were mixed with sample
buffer (62.5 mM Tris hydrochloride, pH 6.8, 10% v/v glycerol, 2%
SDS, 1 mM DTT, and 0.005% bromophenol blue), heated at 95C
for 5 min and then loaded onto a 12% SDS-PAGE gels. After the
electrophoresis, the proteins were transferred onto Immobilon-FL
Transfer Membranes (cat. no.: IPFL00010; Millipore). The mem-
branes were blocked with 5% fat-free milk in Tris-buffered saline
(TBS) for 1 h at room temperature and incubated with the bead el-
uates as primary antibodies in blocking buffer overnight at 4C
(1:100 dilution). The membranes were washed three times in
TBS-Tween (0.05%, v/v) and then incubated for 1 h at room tem-
perature with (HRP)-conjugated secondary antibodies, either goat
anti-rat IgG-HRP H&L (cat. no.: ab97057, Abcam) or rabbit anti-
human IgG-HRP H&L (cat. no.: ab6759, Abcam; 1:1,000 in 5%
fat-free milk in TBS-Tween). The membranes were then washed
three times with TBS-Tween and the bands visualized using
the Immobilon Western Chemiluminescence HRP Substrate (cat.
no.: WBKLS0050, Millipore) and a ChemiDoc Imaging System
(BioRad).DNA Isolation and qPCR
Total DNA from rat blood was purified using a QIAGEN Blood and
Tissue DNA extraction kit (QIAGEN, Hilden, Germany) according
the manufacturer’s instructions and eluted in 200 mL of elution buffer.
Viral genome copy numbers were determined by quantitative polymer-
ase chain reaction (qPCR) using primers that bind to the luciferase
cDNA region: (fwd: 50-ACACCCGAGGGGGATGATAA-30; rev: 50-G
TGTTCGTC TTCGTCCCAGT-30). A standard curve was made by
making serial dilutions of luciferase cis-plasmid in nuclease-free water.
Dialyzed virus stocks were diluted 1:1,000 in nuclease-free water and
qPCR mixtures were made up using the iTaq Universal SYBR Green
Supermix (Bio-Rad Laboratories). The qPCRwas carried out according
to the manufacturer’s instructions in a 7,500 Real-Time PCR System
thermal cycler (Applied Biosystems) with the following thermal cycling
parameters: one cycle of 95C for 5 min followed by 40 cycles of 95C
for 10 s, 58C for 10 s, and 72C for 45 s.Statistical Analysis
Statistical analysis was performed using version 7 of Prism for Mac
(Graphpad). Analysis with the Shapiro-Wilk normality test demon-
strated the absence of a normal distribution of luciferase expression
in several groups. Therefore, group-to-group comparisons were per-
formed using the Mann-Whitney test.SUPPLEMENTAL INFORMATION
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